384 related articles for article (PubMed ID: 37767463)
21. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
22. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
23. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy.
Yang R; Li Y; Wang H; Qin T; Yin X; Ma X
Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562
[TBL] [Abstract][Full Text] [Related]
25. Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.
Agostinetto E; Eiger D; Punie K; de Azambuja E
Curr Oncol Rep; 2021 Mar; 23(5):57. PubMed ID: 33763756
[TBL] [Abstract][Full Text] [Related]
26. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
Anders CK; Abramson V; Tan T; Dent R
Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
[TBL] [Abstract][Full Text] [Related]
27. Recent progress in antibody-based therapeutics for triple-negative breast cancer.
Ning WJ; Liu X; Zeng HY; An ZQ; Luo WX; Xia NS
Expert Opin Drug Deliv; 2022 Jul; 19(7):815-832. PubMed ID: 35738312
[TBL] [Abstract][Full Text] [Related]
28. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
29. Targeting triple negative breast cancer stem cells using nanocarriers.
Dasari N; Guntuku GS; Pindiprolu SKSS
Discov Nano; 2024 Mar; 19(1):41. PubMed ID: 38453756
[TBL] [Abstract][Full Text] [Related]
30. Emerging treatment approaches for triple-negative breast cancer.
Capuozzo M; Celotto V; Santorsola M; Fabozzi A; Landi L; Ferrara F; Borzacchiello A; Granata V; Sabbatino F; Savarese G; Cascella M; Perri F; Ottaiano A
Med Oncol; 2023 Dec; 41(1):5. PubMed ID: 38038783
[TBL] [Abstract][Full Text] [Related]
31. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
[TBL] [Abstract][Full Text] [Related]
32. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA
Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525
[TBL] [Abstract][Full Text] [Related]
33. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
34. Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential.
Das K; Paul S; Ghosh A; Gupta S; Mukherjee T; Shankar P; Sharma A; Keshava S; Chauhan SC; Kashyap VK; Parashar D
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835573
[TBL] [Abstract][Full Text] [Related]
35. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
36. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.
Christenson JL; O'Neill KI; Williams MM; Spoelstra NS; Jones KL; Trahan GD; Reese J; Van Patten ET; Elias A; Eisner JR; Richer JK
Mol Cancer Ther; 2021 Jun; 20(6):1062-1071. PubMed ID: 33722849
[TBL] [Abstract][Full Text] [Related]
37. Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y; Zhu X; Tang C; Guan X; Zhang W
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
[TBL] [Abstract][Full Text] [Related]
38. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.
Nath A; Mitra S; Mistry T; Pal R; Nasare VD
Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991
[TBL] [Abstract][Full Text] [Related]
39. Novel therapeutic strategies in the treatment of triple-negative breast cancer.
Oualla K; El-Zawahry HM; Arun B; Reuben JM; Woodward WA; Gamal El-Din H; Lim B; Mellas N; Ueno NT; Fouad TM
Ther Adv Med Oncol; 2017 Jul; 9(7):493-511. PubMed ID: 28717401
[TBL] [Abstract][Full Text] [Related]
40. Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects.
Khadela A; Soni S; Megha K; Shah AC; Pandya AJ; Kothari N; Shah I; Avinash CB
Med Oncol; 2022 Dec; 40(1):48. PubMed ID: 36520261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]